Olympus Unveils Comprehensive Strategy to Transform Endoscopy-Enabled Care Through Innovation and Workforce Optimization

Olympus Corporation unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence. The strategy aims to accelerate cutting-edge technologies and reinforce Olympus' global leadership in MedTech, improving outcomes for millions of patients worldwide. Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, described this as a pivotal moment for the company, emphasizing their move beyond hardware toward intelligent, integrated care.

The company envisions a future where advanced, minimally invasive endoscopy powered by AI, robotics, and connected digital ecosystems enables earlier detection, improves clinical outcomes, enhances patient safety, and ensures continuity of care. With the world's largest installed base of endoscopy systems and significant unmet clinical needs across the care pathway, Olympus is positioned to scale innovation globally and redefine standards in endoscopy-enabled care. The strategy is built on three strategic pillars: Innovation-driven Growth, Simplicity, and Accountability.

Innovation-driven Growth will focus on expanding leadership in AI-powered endoscopy, robotics and cloud-connected solutions. Simplicity and Accountability will serve as operational accelerators, streamlining processes, empowering teams, and driving sustainable performance. As part of its strategy, Olympus will implement a global organizational transformation to align structure and resources with its strategic priorities. The company expects these changes to yield approximately 24 billion yen in run rate savings and a net reduction of roughly 2,000 positions in the global workforce.

The optimization will simplify organizational layers and expand managerial spans of control, fostering agility and clearer accountability. The implementation period is from fiscal year 2026 to fiscal year 2027, with expected workforce reductions and anticipated savings contingent upon all applicable local employment laws and regulatory requirements. Olympus' integrated growth and transformation plan is designed to deliver sustained value for patients, healthcare providers, and shareholders alike.

The company targets 5% year-on-year revenue growth by fiscal year 2029, annual 100 basis-point growth from fiscal year 2026, more than 10% EPS Compound Annual Growth Rate, and continuous improvement in free cash flow. Capital will be deployed dynamically to support innovation, dividends, share buybacks, and strategic M&A. For more information, visit https://www.olympus-global.com and view the original release on https://www.newmediawire.com.

Olympus also announced several leadership changes effective in 2026. Keith Boettiger, currently Corporate Officer and Co-head of the Gastrointestinal Solutions Division, will be appointed Executive Officer and Gastrointestinal Solutions Division Head effective April 1, 2026. He will succeed Frank Drewalowski, who will transition to Senior Advisor to the Chief Executive Officer. Yasuo Takeuchi will step down as Representative Executive Officer, Executive Chairperson and ESG Officer at the end of March 2026, concluding over four decades of service. Takeuchi led Olympus' transformation into a pure-play MedTech company and cultivated its global Purpose and Core Values during his tenure.